Real-time high-resolution compound imaging allows percutaneous initiation and surveillance in an orthotopic murine pancreatic cancer model

Pancreas

Volumn 36, Issue 2, 2008, Pages 146-152

  Ziske, Carsten ^a   Tiemann, Klaus ^b   Schmidt, Tanja ^a   Nagaraj, Srinivas ^a   Märten, Angela ^a   Schmitz, Volker ^a   Clarenbach, Ricarda ^a   Sauerbruch, Tilman ^a   Schmidt Wolf, Ingo G H ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

C57BL 6 mice; Orthotopic; Pancreas; Pancreatic cancer neoplasm; Ultrasound

Indexed keywords

GEMCITABINE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MODEL; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; INOCULATION; LIVER METASTASIS; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREAS TUMOR; PRIORITY JOURNAL; REAL TIME ECHOGRAPHY; TREATMENT RESPONSE; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; DISEASE COURSE; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; EXPERIMENTAL NEOPLASM; PANCREAS CARCINOMA; PATHOLOGY; TIME; TUMOR CELL LINE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; TIME FACTORS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 45549089896     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181586cd9     Document Type: Article

References (31)

1. Kern S, Hruban R, Hollingsworth MA, et al. A white paper: the product of a pancreas cancer think tank. Cancer Res. 2001;61:4923-4932.
2. Drevs J, Hofmann I, Hugenschmidt H, et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res. 2000;60:4819-4824.
3. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277-285.
4. Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 1999;59:5209-5218.
5. Fidler IJ. Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst. 1995;87:1588-1592.
6. Corbett TH, Roberts BJ, Leopold WR, et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res. 1984;44:717-726.
7. Pestieau SR, Stuart OA, Chang D, et al. Pharmacokinetics of intraperitoneal gemcitabine in a rat model. Tumori. 1998;84:706-711.
8. Eckhard M, Brendel M, Brandhorst D, et al. Can the density of naive pancreatic tissue slices predict human islet isolation and purification outcome? Abstract presented at: 7th World Congress of the IPITA; August 22-25, 1999; Sydney, Australia.
9. Fidler IJ. Orthotopic implantation of human colon carcinomas into nude mice provides a valuable model for the biology and therapy of metastasis. Cancer Metastasis Rev. 1991;10:229-243.
10. Fu X, Guadagni F, Hoffman RM. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci U S A. 1992;89:5645-5649.
11. Furukawa T, Kubota T, Watanabe M, et al. A novel Bpatient-like[ treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice. Cancer Res. 1993;53:3070-3072.
12. Olive KP, Tuveson DA. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res. 2006; 12(18):5277-5287.
13. Sabbah EN, Kadouche J, Ellison D, et al. In vitro and in vivo comparison of DTPA- and DOTA-conjugated antiferritin monoclonal antibody for imaging and therapy of pancreatic cancer. Nucl Med Biol. 2007; 34(3):293-304.
14. Tepel J, Kruse ML, Kapischke M, et al. Adjuvant treatment of pancreatic carcinoma in a clinically adapted mouse resection model. Pancreatology. 2006;6(3):240-247.
15. Tonra JR, Deevi DS, Corcoran E, et al. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res. 2006; 12(7 pt 1):2197-207.
16. Hsu AR, Cai W, Veeravagu A, et al. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. J Nucl Med. 2007;48(3):445-454.
17. Kang SH, Cho HT, Devi S, et al. Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res. 2006;66(24): 11991-11997.
18. Paraskevakou G, Allen C, Nakamura T, et al. Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas. Mol Ther. 2007;15(4): 677-686.
19. Rehemtulla A, Stegman LD, Cardozo SJ, et al. Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia. 2000;2(6):491-495.
20. Xin X, Abrams TJ, Hollenbach PW, et al. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin Cancer Res. 2006; 12(16):4908-4915.
21. Zeamari S, Rumping G, Floot B, et al. In vivo bioluminescence imaging of locally disseminated colon carcinoma in rats. Br J Cancer. 2004; 90(6):1259-1264.
22. Entrekin R, Porter B, Sillesen H, et al. Real-time spatial compound imaging: application to breast, vascular, and musculoskeletal ultrasound. Semin Ultrasound. 2001;22(1):50-64.
23. Jespersen S, Wilhjelm J, Sillesen H. Multi-angle compound imaging. Ultrason Imaging. 1998;20(2):81-102.
24. Bornmann C, Graeser R, Esser N, et al. A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging. Cancer Chemother Pharmacol. 2007. [Epub ahead of print].
25. Weig HJ, Laugwitz KL, Moretti A, et al. Enhanced cardiac contractility after gene transfer of V2 vasopressin receptors In vivo by ultrasound-guided injection or transcoronary delivery. Circulation. 2000;101:1578-1585.
26. Soots A, Lautenschlager I, Krogerus L, et al. An experimental model of chronic renal allograft rejection in the rat using triple drug immunosuppression. Transplantation. 1998;65:42-46.
27. Turnbull DH, Ramsay JA, Shivji GS, et al. Ultrasound backscatter microscope analysis of mouse melanoma progression. Ultrasound Med Biol. 1996;22:845-853.
28. Rooks V, Beecken WD, Iordanescu I, et al. Sonographic evaluation of orthotopic bladder tumors in mice treated with TNP-470, an angiogenic inhibitor. Acad Radiol. 2001;8:121-127.
29. Kraaij R, van Weerden WM, de Ridder CM, et al. Validation of transrectal ultrasonographic volumetry for orthotopic prostate tumours in mice. Lab Anim. 2002;36:165-172.
30. Kusaka N, Nasu Y, Arata R, et al. Transrectal ultrasound for monitoring murine orthotopic prostate tumor. Prostate. 2001;47:118-124.
31. Schmidt T, Ziske C, Märten A, et al. Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model. Cancer Res. 2003;63: 8962-8967.